Xencor Is Maintained at Outperform by RBC Capital
Xencor Analyst Ratings
RBC Capital Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $34
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $27 to $38
Leerink Partners Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $32
Buy Rating Affirmed for Xencor on Promising XmAb819 Developments and Strong Strategic Position
Buy Rating Affirmed for Xencor Amid Strong Drug Pipeline and Financial Health
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $34
Xencor Analyst Ratings
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $21 to $34
Buy Rating Affirmed for Xencor Owing to Strong Pipeline Progress and Financial Stability
RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)
Xencor (XNCR) Receives a Buy From TD Cowen
Xencor: Based on Current Operating Plans, Xencor Expects to End 2024 With Between $475M and $525M in Cash, Cash Equivalents and Marketable Debt Securities
Xencor Analyst Ratings
Xencor Analyst Ratings
RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating
Buy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth Potential
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Neurogene (NGNE)
Xencor Analyst Ratings